{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:00:38Z","timestamp":1789984838900,"version":"4.0.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"DOI":"10.1007\/s40199-026-00664-4","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:08:54Z","timestamp":1789981734000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Personalized neoantigen mRNA vaccines for pancreatic cancer: the role of lipid nanoparticle delivery systems"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0061-1503","authenticated-orcid":false,"given":"Dipayan","family":"Debnath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"issue":"7","key":"664_CR1","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","volume":"18","author":"AP Klein","year":"2021","unstructured":"Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18(7):493\u2013502. https:\/\/doi.org\/10.1038\/s41575-021-00457-x.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"27","key":"664_CR2","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.3748\/wjg.v27.i27.4298","volume":"27","author":"JX Hu","year":"2021","unstructured":"Hu JX, Zhao CF, Chen WB, Liu QC, Li QW, Lin YY, Gao F. Pancreatic cancer: A review of epidemiology, trend, and risk factors. World J Gastroenterol. 2021;27(27):4298\u2013321. https:\/\/doi.org\/10.3748\/wjg.v27.i27.4298.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"664_CR3","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.cgh.2020.02.054","volume":"19","author":"N Khalaf","year":"2021","unstructured":"Khalaf N, El-Serag HB, Abrams HR, Thrift AP. Burden of pancreatic cancer: From epidemiology to practice. Clin Gastroenterol Hepatol. 2021;19(5):876\u201384. https:\/\/doi.org\/10.1016\/j.cgh.2020.02.054.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"664_CR4","doi-asserted-by":"publisher","first-page":"2129884","DOI":"10.1080\/08941939.2022.2129884","volume":"36","author":"HM Kolbeinsson","year":"2023","unstructured":"Kolbeinsson HM, Chandana S, Wright GP, Chung M. Pancreatic cancer: A review of current treatment and novel therapies. J Invest Surg. 2023;36(1):2129884. https:\/\/doi.org\/10.1080\/08941939.2022.2129884.","journal-title":"J Invest Surg"},{"issue":"23","key":"664_CR5","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.3390\/cancers15235577","volume":"15","author":"M Caban","year":"2023","unstructured":"Caban M, Ma\u0142ecka-Wojciesko E. Gaps and opportunities in the diagnosis and treatment of pancreatic cancer. Cancers (Basel). 2023;15(23):5577. https:\/\/doi.org\/10.3390\/cancers15235577.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"664_CR6","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3390\/cancers14040985","volume":"14","author":"S Robatel","year":"2022","unstructured":"Robatel S, Schenk M. Current limitations and novel perspectives in pancreatic cancer treatment. Cancers (Basel). 2022;14(4):985. https:\/\/doi.org\/10.3390\/cancers14040985.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"664_CR7","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s40364-025-00808-9","volume":"13","author":"Z Wang","year":"2025","unstructured":"Wang Z, Gu Y, Sun X, Huang H. Computation strategies and clinical applications in neoantigen discovery towards precision cancer immunotherapy. Biomark Res. 2025;13(1):96. https:\/\/doi.org\/10.1186\/s40364-025-00808-9.","journal-title":"Biomark Res"},{"key":"664_CR8","doi-asserted-by":"publisher","first-page":"1617654","DOI":"10.3389\/fimmu.2025.1617654","volume":"16","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Chen TT, Li X, Lan AL, Ji PF, Zhu YJ, Ma XY. Advances and challenges in neoantigen prediction for cancer immunotherapy. Front Immunol. 2025;16:1617654. https:\/\/doi.org\/10.3389\/fimmu.2025.1617654.","journal-title":"Front Immunol"},{"issue":"11","key":"664_CR9","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.3390\/cancers16112101","volume":"16","author":"G Singh","year":"2024","unstructured":"Singh G, Kutcher D, Lally R, Rai V. Targeting neoantigens in pancreatic ductal adenocarcinoma. Cancers (Basel). 2024;16(11):2101. https:\/\/doi.org\/10.3390\/cancers16112101.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"664_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.18609\/nai.2024.015","volume":"1","author":"J Zhai","year":"2024","unstructured":"Zhai J, Cote T, Chen Y. Challenges and advances of the stability of mRNA delivery therapeutics. Nucleic Acid Insights. 2024;1(2):101\u201313. https:\/\/doi.org\/10.18609\/nai.2024.015.","journal-title":"Nucleic Acid Insights"},{"issue":"2","key":"664_CR11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/pharmaceutics12020102","volume":"12","author":"A Wadhwa","year":"2020","unstructured":"Wadhwa A, Aljabbari A, Lokras A, Foged C, Thakur A. Opportunities and challenges in the delivery of mRNA-based vaccines. Pharmaceutics. 2020;12(2):102. https:\/\/doi.org\/10.3390\/pharmaceutics12020102.","journal-title":"Pharmaceutics"},{"key":"664_CR12","doi-asserted-by":"publisher","first-page":"101705","DOI":"10.1016\/j.cocis.2023.101705","volume":"66","author":"M C\u00e1rdenas","year":"2023","unstructured":"C\u00e1rdenas M, Campbell RA, Arteta MY, Lawrence MJ, Sebastiani F. Review of structural design guiding the development of lipid nanoparticles for nucleic acid delivery. Curr Opin Colloid Interface Sci. 2023;66:101705. https:\/\/doi.org\/10.1016\/j.cocis.2023.101705.","journal-title":"Curr Opin Colloid Interface Sci"},{"issue":"1","key":"664_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40364-021-00315-7","volume":"9","author":"X Zhao","year":"2021","unstructured":"Zhao X, Pan X, Wang Y, Zhang Y. Targeting neoantigens for cancer immunotherapy. Biomark Res. 2021;9(1):61. https:\/\/doi.org\/10.1186\/s40364-021-00315-7.","journal-title":"Biomark Res"},{"key":"664_CR14","doi-asserted-by":"publisher","first-page":"682325","DOI":"10.3389\/fonc.2021.682325","volume":"11","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Liu J. The role of neoantigens in cancer immunotherapy. Front Oncol. 2021;11:682325. https:\/\/doi.org\/10.3389\/fonc.2021.682325.","journal-title":"Front Oncol"},{"issue":"5","key":"664_CR15","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s43018-021-00210-y","volume":"2","author":"AH Pearlman","year":"2021","unstructured":"Pearlman AH, Hwang MS, Konig MF, Hsiue EH, Douglass J, DiNapoli SR, Mog BJ, Bettegowda C, Pardoll DM, Gabelli SB, Papadopoulos N. Targeting public neoantigens for cancer immunotherapy. Nat Cancer. 2021;2(5):487\u201397. https:\/\/doi.org\/10.1038\/s43018-021-00210-y.","journal-title":"Nat Cancer"},{"key":"664_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3389\/fimmu.2020.00027","volume":"11","author":"V Roudko","year":"2020","unstructured":"Roudko V, Greenbaum B, Bhardwaj N. Computational prediction and validation of tumor-associated neoantigens. Front Immunol. 2020;11:27. https:\/\/doi.org\/10.3389\/fimmu.2020.00027.","journal-title":"Front Immunol"},{"issue":"3","key":"664_CR17","doi-asserted-by":"publisher","first-page":"e01111","DOI":"10.1002\/cti2.1111","volume":"9","author":"Q Leng","year":"2020","unstructured":"Leng Q, Tarbe M, Long Q, Wang F. Pre-existing heterologous T-cell immunity and neoantigen immunogenicity. Clin Transl Immunol. 2020;9(3):e01111. https:\/\/doi.org\/10.1002\/cti2.1111.","journal-title":"Clin Transl Immunol"},{"issue":"19","key":"664_CR18","doi-asserted-by":"publisher","first-page":"11624","DOI":"10.3390\/ijms231911624","volume":"23","author":"K Diao","year":"2022","unstructured":"Diao K, Chen J, Wu T, Wang X, Wang G, Sun X, Zhao X, Wu C, Wang J, Yao H, et al. Seq2Neo: A comprehensive pipeline for cancer neoantigen immunogenicity prediction. Int J Mol Sci. 2022;23(19):11624. https:\/\/doi.org\/10.3390\/ijms231911624.","journal-title":"Int J Mol Sci"},{"issue":"49","key":"664_CR19","doi-asserted-by":"publisher","first-page":"eadx8303","DOI":"10.1126\/sciadv.adx8303","volume":"11","author":"JY Kim","year":"2025","unstructured":"Kim JY, An J, Kim S, Jo HY, Lee EJ, Kim M, Cha H, Lee SH, Park HY, Kim SC, et al. B cell-reactive neoantigens boost antitumor immunity. Sci Adv. 2025;11(49):eadx8303. https:\/\/doi.org\/10.1126\/sciadv.adx8303.","journal-title":"Sci Adv"},{"issue":"1","key":"664_CR20","doi-asserted-by":"publisher","first-page":"2096363","DOI":"10.1080\/2162402X.2022.2096363","volume":"11","author":"RS Laureano","year":"2022","unstructured":"Laureano RS, Sprooten J, Vanmeerbeerk I, Borras DM, Govaerts J, Naulaerts S, et al. Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. Oncoimmunology. 2022;11(1):2096363. https:\/\/doi.org\/10.1080\/2162402X.2022.2096363.","journal-title":"Oncoimmunology"},{"issue":"10","key":"664_CR21","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.ccell.2021.07.007","volume":"39","author":"WA Freed-Pastor","year":"2021","unstructured":"Freed-Pastor WA, Lambert LJ, Ely ZA, Pattada NB, Bhutkar A, Eng G, Mercer KL, Garcia AP, Lin L, Rideout WM, et al. The CD155\/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Cancer Cell. 2021;39(10):1342\u2013e136014. https:\/\/doi.org\/10.1016\/j.ccell.2021.07.007.","journal-title":"Cancer Cell"},{"issue":"7913","key":"664_CR22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41586-022-04735-9","volume":"606","author":"M \u0141uksza","year":"2022","unstructured":"\u0141uksza M, Sethna ZM, Rojas LA, Lihm J, Bravi B, Elhanati Y, Soares K, Amisaki M, Dobrin A, Hoyos D, et al. Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Nature. 2022;606(7913):389\u201395. https:\/\/doi.org\/10.1038\/s41586-022-04735-9.","journal-title":"Nature"},{"key":"664_CR23","doi-asserted-by":"publisher","first-page":"1105420","DOI":"10.3389\/fimmu.2023.1105420","volume":"14","author":"N Biswas","year":"2023","unstructured":"Biswas N, Chakrabarti S, Padul V, Jones LD, Ashili S. Designing neoantigen cancer vaccines, trials, and outcomes. Front Immunol. 2023;14:1105420. https:\/\/doi.org\/10.3389\/fimmu.2023.1105420.","journal-title":"Front Immunol"},{"issue":"4","key":"664_CR24","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","volume":"30","author":"M Yarchoan","year":"2024","unstructured":"Yarchoan M, Gane EJ, Marron TU, Perales-Linares R, Yan J, Cooch N, Shu DH, Fertig EJ, Kagohara LT, Bartha G, et al. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial. Nat Med. 2024;30(4):1044\u201353. https:\/\/doi.org\/10.1038\/s41591-024-02894-y.","journal-title":"Nat Med"},{"issue":"5","key":"664_CR25","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1080\/13543784.2021.1896702","volume":"30","author":"S Supabphol","year":"2021","unstructured":"Supabphol S, Li L, Goedegebuure SP, Gillanders WE. Neoantigen vaccine platforms in clinical development: understanding the future of personalized immunotherapy. Expert Opin Investig Drugs. 2021;30(5):529\u201341. https:\/\/doi.org\/10.1080\/13543784.2021.1896702.","journal-title":"Expert Opin Investig Drugs"},{"key":"664_CR26","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jconrel.2024.11.010","volume":"377","author":"B Binici","year":"2025","unstructured":"Binici B, Rattray Z, Zinger A, Perrie Y. Exploring the impact of commonly used ionizable and pegylated lipids on mRNA-LNPs: a combined in vitro and preclinical perspective. J Control Release. 2025;377:162\u201373. https:\/\/doi.org\/10.1016\/j.jconrel.2024.11.010.","journal-title":"J Control Release"},{"issue":"31","key":"664_CR27","doi-asserted-by":"publisher","first-page":"6928","DOI":"10.1021\/acs.jpcb.3c01296","volume":"127","author":"S Dehghani-Ghahnaviyeh","year":"2023","unstructured":"Dehghani-Ghahnaviyeh S, Smith M, Xia Y, Dousis A, Grossfield A, Sur S. Ionizable amino lipids distribution and effects on DSPC\/cholesterol membranes: implications for lipid nanoparticle structure. J Phys Chem B. 2023;127(31):6928\u201339. https:\/\/doi.org\/10.1021\/acs.jpcb.3c01296.","journal-title":"J Phys Chem B"},{"issue":"18","key":"664_CR28","doi-asserted-by":"publisher","first-page":"11329","DOI":"10.1039\/D5NR00433K","volume":"17","author":"L Liu","year":"2025","unstructured":"Liu L, Kim JH, Li Z, Sun M, Northen T, Tang J, et al. PEGylated lipid screening, composition optimization, and structure\u2013activity relationship determination for lipid nanoparticle-mediated mRNA delivery. Nanoscale. 2025;17(18):11329\u201344. https:\/\/doi.org\/10.1039\/D5NR00433K.","journal-title":"Nanoscale"},{"key":"664_CR29","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jconrel.2024.08.030","volume":"375","author":"PS Wei","year":"2024","unstructured":"Wei PS, Thota N, John G, Chang E, Lee S, Wang Y, et al. Enhancing RNA-lipid nanoparticle delivery: organ- and cell-specificity and barcoding strategies. J Control Release. 2024;375:366\u201388. https:\/\/doi.org\/10.1016\/j.jconrel.2024.08.030.","journal-title":"J Control Release"},{"key":"664_CR30","doi-asserted-by":"publisher","first-page":"114416","DOI":"10.1016\/j.addr.2022.114416","volume":"188","author":"CH Albertsen","year":"2022","unstructured":"Albertsen CH, Kulkarni JA, Witzigmann D, Lind M, Petersson K, Simonsen JB. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv Drug Deliv Rev. 2022;188:114416. https:\/\/doi.org\/10.1016\/j.addr.2022.114416.","journal-title":"Adv Drug Deliv Rev"},{"issue":"12","key":"664_CR31","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078\u201394. https:\/\/doi.org\/10.1038\/s41578-021-00358-0.","journal-title":"Nat Rev Mater"},{"issue":"27","key":"664_CR32","doi-asserted-by":"publisher","first-page":"e2301067120","DOI":"10.1073\/pnas.2301067120","volume":"120","author":"L Zheng","year":"2023","unstructured":"Zheng L, Bandara SR, Tan Z, Leal C. Lipid nanoparticle topology regulates endosomal escape and delivery of RNA to the cytoplasm. Proc Natl Acad Sci U S A. 2023;120(27):e2301067120. https:\/\/doi.org\/10.1073\/pnas.2301067120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"664_CR33","doi-asserted-by":"publisher","first-page":"4289","DOI":"10.1039\/D0BM01947J","volume":"9","author":"M Herrera","year":"2021","unstructured":"Herrera M, Kim J, Eygeris Y, Jozic A, Sahay G. Illuminating endosomal escape of polymorphic lipid nanoparticles that boost mRNA delivery. Biomater Sci. 2021;9(12):4289\u2013300. https:\/\/doi.org\/10.1039\/D0BM01947J.","journal-title":"Biomater Sci"},{"issue":"3","key":"664_CR34","doi-asserted-by":"publisher","first-page":"344","DOI":"10.20517\/evcna.2024.19","volume":"5","author":"L Hagedorn","year":"2024","unstructured":"Hagedorn L, J\u00fcrgens DC, Merkel OM, Winkeljann B. Endosomal escape mechanisms of extracellular vesicle-based drug carriers: lessons for lipid nanoparticle design. Extracell Vesicles Circ Nucleic Acids. 2024;5(3):344\u201357. https:\/\/doi.org\/10.20517\/evcna.2024.19.","journal-title":"Extracell Vesicles Circ Nucleic Acids"},{"issue":"1","key":"664_CR35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12943-021-01311-z","volume":"20","author":"Y Wang","year":"2021","unstructured":"Wang Y, Zhang Z, Luo J, Han X, Wei Y, Wei X. mRNA vaccine: a potential therapeutic strategy. Mol Cancer. 2021;20(1):33. https:\/\/doi.org\/10.1186\/s12943-021-01311-z.","journal-title":"Mol Cancer"},{"issue":"7","key":"664_CR36","doi-asserted-by":"publisher","first-page":"945","DOI":"10.3390\/pharmaceutics13070945","volume":"13","author":"C Delehedde","year":"2021","unstructured":"Delehedde C, Even L, Midoux P, Pichon C, Perche F. Intracellular routing and recognition of lipid-based mRNA nanoparticles. Pharmaceutics. 2021;13(7):945. https:\/\/doi.org\/10.3390\/pharmaceutics13070945.","journal-title":"Pharmaceutics"},{"issue":"1","key":"664_CR37","doi-asserted-by":"publisher","first-page":"5659","DOI":"10.1038\/s41467-024-50093-7","volume":"15","author":"K Su","year":"2024","unstructured":"Su K, Shi L, Sheng T, Yan X, Lin L, Meng C, et al. Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation. Nat Commun. 2024;15(1):5659. https:\/\/doi.org\/10.1038\/s41467-024-50093-7.","journal-title":"Nat Commun"},{"issue":"23","key":"664_CR38","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1021\/acs.accounts.1c00550","volume":"54","author":"C Wang","year":"2021","unstructured":"Wang C, Zhang Y, Dong Y. Lipid nanoparticle\u2013mRNA formulations for therapeutic applications. Acc Chem Res. 2021;54(23):4283\u201393. https:\/\/doi.org\/10.1021\/acs.accounts.1c00550.","journal-title":"Acc Chem Res"},{"key":"664_CR39","doi-asserted-by":"publisher","first-page":"922301","DOI":"10.3389\/fimmu.2022.922301","volume":"13","author":"T Huang","year":"2022","unstructured":"Huang T, Peng L, Han Y, Wang D, He X, Wang J, et al. Lipid nanoparticle-based mRNA vaccines in cancers: current advances and future prospects. Front Immunol. 2022;13:922301. https:\/\/doi.org\/10.3389\/fimmu.2022.922301.","journal-title":"Front Immunol"},{"issue":"22","key":"664_CR40","doi-asserted-by":"publisher","first-page":"10988","DOI":"10.3390\/ijms262210988","volume":"26","author":"J Kabut","year":"2025","unstructured":"Kabut J, Stopyra M, Nafalska N, St\u0119pie\u0144 GJ, Miciak M, Jezierza\u0144ski M, et al. mRNA-based neoantigen vaccines in pancreatic ductal adenocarcinoma (PDAC)\u2014a promising avenue in cancer immunotherapy. Int J Mol Sci. 2025;26(22):10988. https:\/\/doi.org\/10.3390\/ijms262210988.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"664_CR41","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.ymthe.2020.09.038","volume":"29","author":"CS Shemesh","year":"2021","unstructured":"Shemesh CS, Hsu JC, Hosseini I, Shen BQ, Rotte A, Twomey P, Girish S, Wu B. Personalized cancer vaccines: clinical landscape, challenges, and opportunities. Mol Ther. 2021;29(2):555\u201370. https:\/\/doi.org\/10.1016\/j.ymthe.2020.09.038.","journal-title":"Mol Ther"},{"issue":"12","key":"664_CR42","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.3390\/pharmaceutics14122682","volume":"14","author":"L Yang","year":"2022","unstructured":"Yang L, Gong L, Wang P, Zhao X, Zhao F, Zhang Z, Li Y, Huang W. Recent advances in lipid nanoparticles for delivery of mRNA. Pharmaceutics. 2022;14(12):2682. https:\/\/doi.org\/10.3390\/pharmaceutics14122682.","journal-title":"Pharmaceutics"},{"issue":"2","key":"664_CR43","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/biochem5020005","volume":"5","author":"H Kong","year":"2025","unstructured":"Kong H. Advances in personalized cancer vaccine development: AI applications from neoantigen discovery to mRNA formulation. BioChem. 2025;5(2):5. https:\/\/doi.org\/10.3390\/biochem5020005.","journal-title":"BioChem"},{"issue":"1","key":"664_CR44","doi-asserted-by":"publisher","first-page":"2652613","DOI":"10.1080\/23723556.2026.2652613","volume":"13","author":"M Parganiha","year":"2026","unstructured":"Parganiha M, Rathored J, Painkra DS. mRNA vaccines in oncology: personalized cancer immunization and neoantigen targeting. Mol Cell Oncol. 2026;13(1):2652613. https:\/\/doi.org\/10.1080\/23723556.2026.2652613.","journal-title":"Mol Cell Oncol"},{"issue":"48","key":"664_CR45","doi-asserted-by":"publisher","first-page":"40733","DOI":"10.1021\/acsnano.5c14753","volume":"19","author":"AE Nel","year":"2025","unstructured":"Nel AE, Luo L, Liao YP, Wang X. Reprogramming immunosuppressive niches and the cancer immunity cycle in pancreatic cancer with neoantigen mRNA plus immune adjuvant nanocarrier strategies. ACS Nano. 2025;19(48):40733\u201345. https:\/\/doi.org\/10.1021\/acsnano.5c14753.","journal-title":"ACS Nano"},{"key":"664_CR46","doi-asserted-by":"publisher","first-page":"1104860","DOI":"10.3389\/fimmu.2023.1104860","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X, Xu Z, Dai X, Zhang X, Wang X. Research progress of neoantigen-based dendritic cell vaccines in pancreatic cancer. Front Immunol. 2023;14:1104860. https:\/\/doi.org\/10.3389\/fimmu.2023.1104860.","journal-title":"Front Immunol"},{"issue":"8056","key":"664_CR47","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","volume":"639","author":"Z Sethna","year":"2025","unstructured":"Sethna Z, Guasp P, Reiche C, Milighetti M, Ceglia N, Patterson E, Lihm J, Payne G, Lyudovyk O, Rojas LA, Pang N, et al. RNA neoantigen vaccines prime long-lived CD8\u2009+\u2009T cells in pancreatic cancer. Nature. 2025;639(8056):1042\u201351. https:\/\/doi.org\/10.1038\/s41586-024-08508-4.","journal-title":"Nature"},{"key":"664_CR48","doi-asserted-by":"publisher","first-page":"1039226","DOI":"10.3389\/fimmu.2022.1039226","volume":"13","author":"H Peng","year":"2022","unstructured":"Peng H, Li L, Zuo C, Chen MY, Zhang X, Myers NB, Hogg GD, DeNardo DG, Goedegebuure SP, Hawkins WG, Gillanders WE. Combination TIGIT\/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer. Front Immunol. 2022;13:1039226. https:\/\/doi.org\/10.3389\/fimmu.2022.1039226.","journal-title":"Front Immunol"},{"issue":"16 Suppl","key":"664_CR49","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2022.40.16_suppl.2516","volume":"40","author":"VP Balachandran","year":"2022","unstructured":"Balachandran VP, Rojas LA, Sethna Z, Soares K, Derhovanessian E, Mueller F, Yadav M, Basturk O, Gonen M, Wei AC, D\u2019Angelica MI, et al. Phase I trial of adjuvant autogene cevumeran, an individualized mRNA neoantigen vaccine, for pancreatic ductal adenocarcinoma. J Clin Oncol. 2022;40(16 Suppl):2516. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.2516.","journal-title":"J Clin Oncol"},{"issue":"1","key":"664_CR50","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-024-03334-7","volume":"31","author":"J Lopez","year":"2025","unstructured":"Lopez J, Powles T, Braiteh F, Siu LL, LoRusso P, Friedman CF, Balmanoukian AS, Gordon M, Yachnin J, Rottey S, Karydis I, et al. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Nat Med. 2025;31(1):152\u201364. https:\/\/doi.org\/10.1038\/s41591-024-03334-7.","journal-title":"Nat Med"},{"key":"664_CR51","doi-asserted-by":"publisher","unstructured":"Ahmed S, Mazhar MS, Shabbir MF. Neoantigen-based cancer vaccines: current innovations, challenges and future directions in personalized immunotherapy. Cancer Immunol Connect. 2024;1:2024.0001 https:\/\/doi.org\/10.69709\/CIConnect.2024.194763.","DOI":"10.69709\/CIConnect.2024.194763"},{"issue":"2","key":"664_CR52","doi-asserted-by":"publisher","first-page":"75","DOI":"10.54963\/ti.v10i2.2355","volume":"10","author":"SK Chaturvedi","year":"2026","unstructured":"Chaturvedi SK, Sharma A, Chauhan R, Dubey SK, Mithlesh, Sharma S, Bhatnagar P. Personalized neoantigen-based cancer vaccines have advanced rapidly, though several key challenges remain. Trends Immunother. 2026;10(2):75\u201388. https:\/\/doi.org\/10.54963\/ti.v10i2.2355.","journal-title":"Trends Immunother"},{"issue":"2","key":"664_CR53","doi-asserted-by":"publisher","first-page":"e20220007","DOI":"10.1002\/INMD.20220007","volume":"1","author":"M Lu","year":"2023","unstructured":"Lu M, Shao W, Xing H, Huang Y. Extracellular vesicle-based nucleic acid delivery. Interdiscip Med. 2023;1(2):e20220007. https:\/\/doi.org\/10.1002\/INMD.20220007.","journal-title":"Interdiscip Med"},{"issue":"6","key":"664_CR54","doi-asserted-by":"publisher","first-page":"20240109","DOI":"10.1002\/EXP.20240109","volume":"5","author":"Q Li","year":"2025","unstructured":"Li Q, Xing H, Naeem A, Zhang K, Zheng A, Huang Y, Lu M. Extracellular vesicle-based mRNA therapeutics and vaccines. Exploration. 2025;5(6):20240109. https:\/\/doi.org\/10.1002\/EXP.20240109.","journal-title":"Exploration"},{"key":"664_CR55","doi-asserted-by":"publisher","first-page":"103085","DOI":"10.1016\/j.nantod.2026.103085","volume":"69","author":"W Zang","year":"2026","unstructured":"Zang W, Peng J, Xing H, Huang Y, Lu M. The dual facets of B cell immunity: from pathogenic drivers to theranostic tools. Nano Today. 2026;69:103085. https:\/\/doi.org\/10.1016\/j.nantod.2026.103085.","journal-title":"Nano Today"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00664-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-026-00664-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00664-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:08:55Z","timestamp":1789981735000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40199-026-00664-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":55,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["664"],"URL":"https:\/\/doi.org\/10.1007\/s40199-026-00664-4","relation":{},"ISSN":["2008-2231"],"issn-type":[{"value":"2008-2231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"10 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Artificial intelligence (AI)-assisted tools were used solely to support language refinement, organization of content, and improvement of manuscript readability. All scientific interpretation, literature selection, fact verification, and final manuscript preparation were performed by the authors, who take full responsibility for the accuracy and integrity of the content.","order":2,"name":"Ethics","label":"<b>AI Disclosure<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"82"}}